Let’s dive into that recent news below and learn a bit more about Genfit while we’re at it!
- This agreement gives Ipsen the exclusive worldwide rights to develop, manufacture, and commercialize elafibranor.
- This is an investigational treatment from Genfit for patients suffering from Primary Biliary Cholangitis (PBC).
- The deal doesn’t stop there.
- It also gives Ipsen access to future clinical programs led by Genfit.
- Investors will also note that this deal is long-term in nature.
- That includes Ipsen making a €28m investment in the company.
- This has it acquiring newly-issued shares of GNFT stock that give it an 8% stake in the company.
- In addition to this, Genfit also announced its acquisition of rights to develop and commercialize GNS561.
- This is an investigational cholangiocarcinoma treatment from Genoscience Pharma.
- The rights include the U.S., Canada, and Europe.
- Genfit is a late-stage biopharmaceutical company with a focus on developing treatments for severe chronic liver diseases.
- The company was founded in 1999 and operates out of its headquarters in Nord, France.
- GNFT stock is experiencing heavy trading on today’s news.
- That has some 19 million shares on the move as of this writing.
- To put that in perspective, the company’s daily average trading volume is closer to only about 7,000 shares.
GNFT stock is up 46.8% as of Friday morning and is only down about 2% since the start of the year.
Investors searching for more stock market news today will want to stick around!
InvestorPlace houses all the most recent stock coverage traders need to know about today. That includes everything investors need to know about Alibaba (NYSE:BABA), Novavax (NASDAQ:NVAX), and Futu Holdings (NASDAQ:FUTU) shares today. You can get all that info from the following links!
More Friday Stock Market News
- BABA Stock Alert: 18 Key Takeaways From Alibaba Investor Day 2021
- NVAX Stock Pops as the WHO Grants Novavax’s Vaccine Emergency Use. 8 Things to Know.
- FUTU Stock: What Is Going on With Futu Holdings Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed